$73.24
1.80% day before yesterday
NYSE, Sep 06, 10:10 pm CET
ISIN
US4050241003
Symbol
HAE
Sector

Haemonetics Corporation Stock price

$73.24
-12.96 15.03% 1M
-4.21 5.44% 6M
-12.27 14.35% YTD
-15.50 17.47% 1Y
+8.67 13.43% 3Y
-54.30 42.57% 5Y
+37.22 103.33% 10Y
NYSE, Closing price Fri, Sep 06 2024
-1.34 1.80%
ISIN
US4050241003
Symbol
HAE
Sector

Key metrics

Market capitalization $3.75b
Enterprise Value $4.63b
P/E (TTM) P/E ratio 32.81
EV/FCF (TTM) EV/FCF 63.42
EV/Sales (TTM) EV/Sales 3.47
P/S ratio (TTM) P/S ratio 2.81
P/B ratio (TTM) P/B ratio 4.14
Revenue growth (TTM) Revenue growth 9.47%
Revenue (TTM) Revenue $1.33b
EBIT (operating result TTM) EBIT $195.38m
Free Cash Flow (TTM) Free Cash Flow $72.96m
Cash position $344.43m
EPS (TTM) EPS $2.23
P/E forward 22.49
P/S forward 2.68
EV/Sales forward 3.31
Short interest 15.42%
Show more

Is Haemonetics Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Haemonetics Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Haemonetics Corporation forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Haemonetics Corporation forecast:

Buy
75%
Hold
25%

Financial data from Haemonetics Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
1,334 1,334
9% 9%
100%
- Direct Costs 654 654
9% 9%
49%
680 680
10% 10%
51%
- Selling and Administrative Expenses 327 327
16% 16%
25%
- Research and Development Expense 54 54
6% 6%
4%
299 299
5% 5%
22%
- Depreciation and Amortization 103 103
10% 10%
8%
EBIT (Operating Income) EBIT 195 195
3% 3%
15%
Net Profit 115 115
16% 16%
9%

In millions USD.

Don't miss a Thing! We will send you all news about Haemonetics Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Haemonetics Corporation Stock News

Neutral
PRNewsWire
24 days ago
BOSTON , Aug. 15, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, today announced the full market release of its VASCADE MVP® XL mid-bore venous closure system. The VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® port...
Neutral
Seeking Alpha
about one month ago
Haemonetics Corporation (NYSE:HAE ) Q1 2025 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Olga Guyette – Vice President, Investor Relations and Treasury Chris Simon – Chief Executive Officer James D'Arecca – Chief Financial Officer Conference Call Participants Anthony Petrone – Mizuho Americas Mike Matson – Needham Andrew Cooper – Raymond James Larry Solow – CJS Securi...
Neutral
PRNewsWire
about one month ago
Financial release accessible online BOSTON , Aug. 8, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal year 2025, which ended June 29, 2024, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 ...
More Haemonetics Corporation News

Company Profile

Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following geographical segments: Japan, EMEA (Europe, the Middle East, and Africa), North America Plasma, and All Other. Its products include surgical and diagnostic devices, blood and plasma center devices, blood center software, hospital software, and plasma center software. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Braintree, MA.

Head office United States
CEO Christopher Simon
Employees 3,657
Founded 1971
Website www.haemonetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today